{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:54:24Z","timestamp":1791222864561,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>AtLaS was a single-arm pilot study that demonstrated promising efficacy and safety of treatment simplification to a dual regimen with atazanavir\/ritonavir\u200a+\u200alamivudine in virologically suppressed HIV-positive patients. Here, we report data from the 144 week follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>At baseline, patients treated with a three-drug atazanavir\/ritonavir-based regimen were switched to 300\/100 mg of atazanavir\/ritonavir plus 300 mg of lamivudine once daily. Major clinical events, laboratory parameters, neurocognitive performance, bone composition and body fat distribution were monitored. Treatment failure was defined as a discontinuation\/switch of the regimen or virological failure (HIV-RNA &amp;gt;50 copies\/mL in two consecutive determinations or a single level above 1000 copies\/mL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After 144 weeks, 9\/40 (22.5%) treatment failures occurred, including two virological failures (Weeks 48 and 53, without resistance). A significant increase in the CD4 count was observed at Week 96 (+124 cells\/mm3; P\u200a=\u200a0.002) and Week 144 (+94 cells\/mm3; P\u200a=\u200a0.008). After 144 weeks, a significant increase in total cholesterol (+25 mg\/dL; P\u200a=\u200a0.001), HDL cholesterol (+6 mg\/dL; P\u200a=\u200a0.024) and LDL cholesterol (+12 mg\/dL; P\u200a=\u200a0.008) was observed, without any change in triglyceride levels, total cholesterol\/HDL ratio or LDL\/HDL ratio. A significant increase in the estimated glomerular filtration rate (+25 mL\/min\/1.73 m2; P\u200a&amp;lt;\u200a0.001) and lumbar spine T-score and Z-score (+0.2, P\u200a=\u200a0.011; and +0.35, P\u200a=\u200a0.001, respectively) and a decrease in trunk fat (\u22121.898 g; P\u200a=\u200a0.005) were also observed. Neurocognitive function did not decline over time. Concerning safety, 10 moderate to severe adverse events were recorded in eight patients; overall seven cases of renal colic (possibly treatment related) were observed, leading to a discontinuation of treatment in two patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Data from the 144 week follow-up suggested good long-term efficacy of the simplification strategy that was investigated, with rare virological failure and a potential for improvement of the CD4 count, renal function and bone mineral density. This strategy warrants further investigation in a randomized trial.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkv037","type":"journal-article","created":{"date-parts":[[2015,8,4]],"date-time":"2015-08-04T01:29:31Z","timestamp":1438651771000},"page":"1843-1849","source":"Crossref","is-referenced-by-count":34,"title":["Efficacy and safety of treatment simplification to atazanavir\/ritonavir\u200a+\u200alamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study"],"prefix":"10.1093","volume":"70","author":[{"given":"A.","family":"Mondi","sequence":"first","affiliation":[{"name":"1 \u00a0Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fabbiani","sequence":"additional","affiliation":[{"name":"1 \u00a0Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Ciccarelli","sequence":"additional","affiliation":[{"name":"1 \u00a0Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Colafigli","sequence":"additional","affiliation":[{"name":"1 \u00a0Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"D'Avino","sequence":"additional","affiliation":[{"name":"1 \u00a0Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Borghetti","sequence":"additional","affiliation":[{"name":"1 \u00a0Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Gagliardini","sequence":"additional","affiliation":[{"name":"1 \u00a0Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Cauda","sequence":"additional","affiliation":[{"name":"1 \u00a0Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"De Luca","sequence":"additional","affiliation":[{"name":"2 \u00a0Infectious Diseases Unit, Siena University Hospital, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Di Giambenedetto","sequence":"additional","affiliation":[{"name":"1 \u00a0Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,2,26]]},"reference":[{"key":"2022020123411581900_DKV037C1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/QAI.0b013e3181a56de5","article-title":"OK04 Study Group. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis","volume":"51","author":"Arribas","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022020123411581900_DKV037C2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1468-1293.2012.00989.x","article-title":"The MONET trial: week 144 analysis of the efficacy of darunavir\/ritonavir (DRV\/r) monotherapy versus DRV\/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load &lt;50 HIV-1 RNA copies\/mL at baseline","volume":"13","author":"Arribas","year":"2012","journal-title":"HIV Med"},{"key":"2022020123411581900_DKV037C3","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1097\/QAD.0b013e32833dec20","article-title":"Efficacy of darunavir\/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136","volume":"24","author":"Katlama","year":"2010","journal-title":"AIDS"},{"key":"2022020123411581900_DKV037C4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1310\/hct1205-255","article-title":"Examination of noninferiority, safety, and tolerability of lopinavir\/ritonavir and raltegravir compared with lopinavir\/ritonavir and tenofovir\/ emtricitabine in antiretroviral-na\u00efve subjects: the progress study, 48-week results","volume":"12","author":"Reynes","year":"2011","journal-title":"HIV Clin Trials"},{"key":"2022020123411581900_DKV037C5","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/jac\/dkt007","article-title":"Safety and feasibility of treatment simplification to atazanavir\/ritonavir\u200a+\u200alamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors\u200a+\u200aatazanavir\/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study)","volume":"68","author":"Di Giambenedetto","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2022020123411581900_DKV037C6","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1212\/01.WNL.0000287431.88658.8b","article-title":"Updated research nosology for HIV-associated neurocognitive disorders","volume":"69","author":"Antinori","year":"2007","journal-title":"Neurology"},{"key":"2022020123411581900_DKV037C7","doi-asserted-by":"crossref","first-page":"e1004078","DOI":"10.1371\/journal.ppat.1004078","article-title":"HIV-infected individuals with low CD4\/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality","volume":"10","author":"Serrano-Villar","year":"2014","journal-title":"PLoS Pathog"},{"key":"2022020123411581900_DKV037C8","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1097\/QAD.0000000000000407","article-title":"MODAt Study Group. Simplification to atazanavir\/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results","volume":"28","author":"Castagna","year":"2014","journal-title":"AIDS"},{"key":"2022020123411581900_DKV037C9","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1473-3099(14)70736-4","article-title":"on behalf of the GARDEL Study Group. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial","volume":"14","author":"Cahn","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2022020123411581900_DKV037C10","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1089\/aid.2011.0336","article-title":"A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir\/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study","volume":"28","author":"Ofotokun","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2022020123411581900_DKV037C11","article-title":"Non-inferiority of dual-therapy (DT) with lopinavir\/ritonavir (LPV\/r) plus lamivudine (3TC) vs triple-therapy (TT) with LPV\/r plus two nucleos(t)ides (NRTIs) for maintenance of HIV-1 viral suppression: 48-week results of the OLE study","author":"Gatell"},{"key":"2022020123411581900_DKV037C12","article-title":"Maraviroc (MVC) once daily with darunavir\/ritonavir (DRV\/r) in a 2-drug regimen compared to emtricitabine\/tenofovir (TDF\/FTC) with DRV\/r: 48-week results from MODERN (Study A4001095)","author":"Stellbrink"},{"key":"2022020123411581900_DKV037C13","article-title":"HARNESS study: ritonavir-boosted atazanavir (ATV\/r)+raltegravir (RAL) switch study in virologically suppressed, HIV-1-infected patients","author":"Van Lunzen"},{"key":"2022020123411581900_DKV037C14","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1016\/S0140-6736(14)61170-3","article-title":"Ritonavir-boosted darunavir combined with raltegravir or tenofovir\u2013emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001\/ANRS143 randomised non-inferiority trial","volume":"384","author":"Raffi","year":"2014","journal-title":"Lancet"},{"key":"2022020123411581900_DKV037C15","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1097\/QAD.0b013e32834a1cd6","article-title":"Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir","volume":"25","author":"Rockwood","year":"2011","journal-title":"AIDS"},{"key":"2022020123411581900_DKV037C16","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/cid\/cis621","article-title":"High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy","volume":"55","author":"Hamada","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2022020123411581900_DKV037C17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jinf.2011.02.004","article-title":"Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients","volume":"62","author":"Fabbiani","year":"2011","journal-title":"J Infect"},{"key":"2022020123411581900_DKV037C18","article-title":"Switching to dual therapy (atazanavir\/ritonavir+ lamivudine) vs. standard triple therapy (atazanavir\/ritonavir+2 nucleos[t]ides) is safe and effective in virologically suppressed patients: 48-week results of a randomized clinical trial (SALT study)","author":"Perez-Molina"},{"issue":"Suppl 3","key":"2022020123411581900_DKV037C19","doi-asserted-by":"crossref","first-page":"19808","DOI":"10.7448\/IAS.17.4.19808","article-title":"Simplification to atazanavir\/ritonavir +lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial","volume":"17","author":"Fabbiani","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"2022020123411581900_DKV037C20","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00126334-200408150-00003","article-title":"Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV","volume":"36","author":"Squires","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022020123411581900_DKV037C21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/apc.2011.0092","article-title":"Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir\/ritonavir through 96 weeks in the CASTLE study","volume":"2","author":"McDonald","year":"2012","journal-title":"AIDS Patient Care STDS"},{"key":"2022020123411581900_DKV037C22","article-title":"Efficacy and tolerability of atazanavir, raltegravir, or darunavir with FTC\/tenofovir: ACTG 5257","author":"Landovitz"},{"issue":"Suppl 3","key":"2022020123411581900_DKV037C23","doi-asserted-by":"crossref","first-page":"19538","DOI":"10.7448\/IAS.17.4.19538","article-title":"No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting","volume":"17","author":"Farr","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"2022020123411581900_DKV037C24","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/jac\/dkq464","article-title":"Lipid-lowering effect of tenofovir in HIV-infected patients","volume":"66","author":"Fabbiani","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2022020123411581900_DKV037C25","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/QAD.0b013e328351f68f","article-title":"Association of tenofovir exposure with kidney disease risk in HIV infection","volume":"26","author":"Scherzer","year":"2012","journal-title":"AIDS"},{"key":"2022020123411581900_DKV037C26","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/656417","article-title":"ASSERT Study Group. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study","volume":"51","author":"Stellbrink","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2022020123411581900_DKV037C27","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/infdis\/jir188","article-title":"Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202","volume":"203","author":"McComsey","year":"2011","journal-title":"J Infect Dis"},{"key":"2022020123411581900_DKV037C28","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/cid\/cir968","article-title":"Adolescent Medicine Trials Network (ATN) for HIV\/AIDS Interventions 063 study team. Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial","volume":"54","author":"Havens","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2022020123411581900_DKV037C29","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/cid\/ciq158","article-title":"Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population","volume":"52","author":"Dao","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2022020123411581900_DKV037C30","doi-asserted-by":"crossref","article-title":"Effects of switching to PI monotherapy on measures of lipoatrophy: meta-analysis of six randomized HIV clinical trials","author":"Arribas","DOI":"10.7448\/IAS.15.6.18281"},{"key":"2022020123411581900_DKV037C31","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1468-1293.2012.01004.x","article-title":"Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir\/ritonavir monotherapy versus darunavir\/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 substudy","volume":"13","author":"Valantin","year":"2012","journal-title":"HIV Med"},{"key":"2022020123411581900_DKV037C32","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1097\/QAD.0b013e328361d25d","article-title":"Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density","volume":"27","author":"Erlandson","year":"2013","journal-title":"AIDS"},{"key":"2022020123411581900_DKV037C33","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1086\/424665","article-title":"AIDS Clinical Trial Group 892 Team. Changes in weight and lean body mass during highly active antiretroviral therapy","volume":"39","author":"Shikuma","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2022020123411581900_DKV037C34","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1086\/498022","article-title":"CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study","volume":"41","author":"McDermott","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2022020123411581900_DKV037C35","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1086\/644769","article-title":"Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial","volume":"49","author":"Martin","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2022020123411581900_DKV037C36","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/QAD.0b013e32814e6b1c","article-title":"The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial","volume":"21","author":"Vernazza","year":"2007","journal-title":"AIDS"},{"key":"2022020123411581900_DKV037C37","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1093\/cid\/ciu640","article-title":"A prospective cohort study of neurocognitive function in aviremic HIV-infected patients treated with 1 or 3 antiretrovirals","volume":"59","author":"P\u00e9rez-Valero","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2022020123411581900_DKV037C38","article-title":"PIVOT Trial Group. Randomised controlled trial of a PI monotherapy switch strategy for long-term HIV management","author":"Paton"},{"issue":"Suppl 3","key":"2022020123411581900_DKV037C39","first-page":"196564","article-title":"CNS safety at 48-week of switching to ATV\/r plus 3TC or two nucleos(t)ides in HIV-suppressed patients on stable ART: the SALT neurocognitive sub-study","volume":"17","author":"Valero-Perez","year":"2014","journal-title":"J Int AIDS Soc"},{"issue":"Suppl 3","key":"2022020123411581900_DKV037C40","doi-asserted-by":"crossref","first-page":"19526","DOI":"10.7448\/IAS.17.4.19526","article-title":"Analysis of neurocognitive function and CNS endpoints in the PROTEA trial: darunavir\/ritonavir with or without nucleoside analogues","volume":"17","author":"Clarke","year":"2014","journal-title":"J Int AIDS Soc"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/70\/6\/1843\/42358429\/jac_70_6_1843.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/70\/6\/1843\/42358429\/jac_70_6_1843.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T10:21:02Z","timestamp":1718014862000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/70\/6\/1843\/729820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,26]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,2,26]]},"published-print":{"date-parts":[[2015,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkv037","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,6]]},"published":{"date-parts":[[2015,2,26]]}}}